Literature DB >> 19574086

Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).

Laura D Locati1, Federica Perrone, Marco Losa, Micol Mela, Paola Casieri, Marta Orsenigo, Barbara Cortelazzi, Tiziana Negri, Elena Tamborini, Pasquale Quattrone, Paolo Bossi, Gaetana Rinaldi, Cristiana Bergamini, Rosa G Calderone, Cecilia Liberatoscioli, Lisa Licitra.   

Abstract

Salivary gland carcinomas (SGCs) are rare tumors encompassing a wide spectrum of histologic/biologic entities. Standard non-surgical treatments are ineffective in case of advanced disease. Our aim was to analyze SGCs deregulation gene profiles that could become target for innovative treatment options. Samples from 139 patients with primary, recurrent and/or metastatic SGCs were investigated by immunohistochemistry for protein encoded by tyrosine kinases receptors (TKRs) i.e. c-kit, HER2, EGFR and hormonal receptors, i.e. androgen (AR), estrogen (ER) and progesterone receptors (PgR). In 26 cases, the HER2 immunohistochemical analysis was complemented by fluorescence in-situ hybridization analysis. EGFR was the most expressed TKRs (71%) and it was found across all histotypes. c-Kit expression was mainly restricted to adenoid cystic carcinoma (78%) while HER2 expression, mostly sustained by gene amplification, correlated with salivary duct carcinoma (SDC) in 44% of cases and adenocarcinoma, not otherwise specified (AD, NOS) in 21% of cases. With respect to histogenetic classification, TKRs expression occurred more often in tumors derived from intercalated duct rather than excretory ones with the only exception of HER2. AR was found in 13% of samples, restricted to SDC and AD, NOS and it was co-expressed with HER2 in more than half of the SDC cases. ER and PgR positivity was never detected. This TK-hormonal receptors analysis identify a histotype-specific profiles that could be exploited for better selecting patients for innovative treatment within prospective studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574086     DOI: 10.1016/j.oraloncology.2009.05.635

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  39 in total

1.  Breast metastasis of salivary duct carcinoma in a patient: a case report.

Authors:  Shuangshuang Guo; Jun Yao
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.

Authors:  Yoshitsugu Mitani; Pulivarthi H Rao; Sankar N Maity; Yu-Chen Lee; Renata Ferrarotto; Julian C Post; Lisa Licitra; Scott M Lippman; Merrill S Kies; Randal S Weber; Carlos Caulin; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Authors:  Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2019-11-26       Impact factor: 12.531

Review 4.  Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.

Authors:  Abdullah Mislat Alotaibi; Mohammed Ali Alqarni; Abdelrahman Alnobi; Bassel Tarakji
Journal:  J Clin Diagn Res       Date:  2015-02-01

5.  Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.

Authors:  Laura D Locati; Federica Perrone; Barbara Cortelazzi; Martina Imbimbo; Paolo Bossi; Paolo Potepan; Enrico Civelli; Gaetana Rinaldi; Pasquale Quattrone; Lisa Licitra; Silvana Pilotti
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

6.  Developing androgen receptor targeting for salivary gland cancers.

Authors:  A L Ho
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

7.  Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance.

Authors:  Li Zhang; Yoshitsugu Mitani; Carlos Caulin; Pulivarthi H Rao; Merrill S Kies; Pierre Saintigny; Nianxiang Zhang; Randal S Weber; Scott M Lippman; Adel K El-Naggar
Journal:  Am J Pathol       Date:  2013-04-10       Impact factor: 4.307

8.  Trastuzumab for the treatment of salivary duct carcinoma.

Authors:  Sewanti A Limaye; Marshall R Posner; Jeffrey F Krane; Maria Fonfria; Jochen H Lorch; Deborah A Dillon; Aditya V Shreenivas; Roy B Tishler; Robert I Haddad
Journal:  Oncologist       Date:  2013-02-21

9.  Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Authors:  Pierre Saintigny; Yoshitsugu Mitani; Kristen B Pytynia; Renata Ferrarotto; Dianna B Roberts; Randal S Weber; Merrill S Kies; Sankar N Maity; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Cancer       Date:  2018-10-05       Impact factor: 6.860

Review 10.  Molecular Pathology and Biomarkers.

Authors:  Patrick K Ha; Göran Stenman
Journal:  Adv Otorhinolaryngol       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.